Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26569ArticlesСтатьиResearch ArticleZnachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezyЗначение таксанов в неоадъювантной терапии рака молочной железыBozhokA AБожокА АSemiglazovV FСемиглазовВ ФKletsel'A EКлетсельА ЕArzumanovA SАрзумановА СIvanovaO AИвановаО АSemiglazovV VСемиглазовВ ВГУН НИИ онкологии им. проф. Н.Н.Петрова, Санкт-ПетербургКлиника онкологии и гинекологии, Оснабрюк, ГерманияЦентральный научно-исследовательский рентгенорадиологический институт, Санкт-ПетербургСанкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова1503200571VOL 7, NO1 (2005)ТОМ 7, №1 (2005)101309042020Copyright ©; 2005, Consilium MedicumCopyright ©; 2005, ООО "Консилиум Медикум"2005Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26569

Современный подход к лечению местно-распространенного РМЖ состоит в последовательном назначении системной терапии и местно-регионального воздействия. Анализ результатов нескольких неконтролируемых исследований показал, что первичная химиотерапия как индукционное лечение значительно увеличивает безрецидивный период и общую выживаемость у больных местно-распространенным РМЖ. Успехи первичной химиотерапии при местно-распространенном РМЖ не вызывают сомнений, однако целесообразность ее использования при ранних операбельных формах заболевания все еще является предметом дискуссий. Результаты продолжающихся исследований очень важны для понимания значения таксанов в неоадъювантной терапии РМЖ. Непосредственная эффективность таксанов достаточно высока и имеющиеся результаты рандомизированных исследований позволяют уже сегодня использовать комбинации таксанов и антрациклинов на предоперационном этапе в клинической практике. Проследив отдаленные результаты различных вариантов лечения, мы сможем понять, приводит ли использование таксанов к увеличению общей и безрецидивной выживаемости, какие комбинации и режимы введения наиболее эффективны, существуют ли определенные группы больных, у которых адъювантная и неоадъювантная терапия таксанами наиболее оправдана. Поскольку возможность излечения РМЖ основывается на адекватном хирургическом вмешательстве и эффективной системной терапии, результаты продолжающихся рандомизированных исследований III фазы очень важны для определения стандартов лечения.

HER-2рак молочной железытерапиятаксаныэффективностьрежим введениякомбинациянеоадъювантная терапияHortobagyi G.N, Buzdar A.I, Strom E.A et al. Primary chemotherapy for early and advanced breast cancer. Cancer Let 1995; 90: 103-9.Mauriac L, Mac Grogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carvinoma larger than 3 cm: a unicentre randomized trial with 124-month median follow - up. Ann Oncol 1999; 10: 47-52.Powles T.J, Hickish T.F, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-52.Scholl S.M, Asselain B, Beuzeboc P et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients tumours considered too large for breast conserving surgery. An update. Proc Am Soc Clin Oncol 1995; 14: abstr. 200.Semiglazov V.F, Topuzov E.E, Bavli Y.L et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5: 591-5.Van der Hage J.A, van der Velde, Julien J.P et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-37.Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine year results from National Surgical Breast and Bowel Project B-18. J Natl cancer Inst Monogr 2001; 30: 96-102.Топузов Э.Э. Пути оптимизации хирургического, комбинированного лечения рака молочной железы и реабилитации больных в послеоперационном периоде. Автореф. дис.. д - ра мед. наук, 2004.Chollet P, Amat S, Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86 (7): 1041-6.Kuerer H.M, Newman L.A, Smith T.L et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin - based neoadjuvant chemotherapy. J Clin Oncol 1999; 17 (2): 441-4.Sataloff D.M, Mason B.A, Prestipino A.J et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180 (3): 297-306.Holmes F.A, Walterrs R.S, Theriault R.L et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.Reichman B.S, Seidman A.D, Crown J.P.A et al. Paclitaxel and recombinant human granulocyte colony - stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.Sendman A.D, Reichman B.S, Crown J.P et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer. Activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9.Abrams J.S, Vena D.A, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995; 13: 2056-65.Nabholtz J.M, Senn H.J, Bezwoda W.R et al. Prosrective randomized trial of docetaxel versus mitomycin C plus vinblastin in patients with metastatic breast cancer progressing despite previous anthracycline - containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54.Semiglazov V.F, Bojok A.A, Arzumanov A.S et al. Neoadjuvant chemotherapy paclitaxel + doxorubicin (PD) vs fluorouracil + doxorubicin + cyclophosphamide (FAC) in locally advanced breast cancer: Clinical and pathological response. Eur J Cancer 2001; 37 (Suppl. 6): 166.Buzdar A.U, Singletary S.E, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Сancer Res 2002; 8: 1073-9.Green M.C, Buzdar A.U, Smith T et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3 weeks (Q3wk) P therapy (tx) followed by FAC - final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21: abstr. 135.Ponillart P, Fumoleau R, Romieu G et al: Final results of a phase II randomized parallel study of doxorubicin|cyclophosphamide (AC) and doxorubicin|Taxol (paclitaxel) (AT) as neoadjuvant treatment of local - regional breast cancer. Proc Am Soc Clin Oncol 1999; 18: abstr. 275.Fumoleau P, Tubiana-Hulin M, Ronieu G et al. A randomized study of 4 versus 6 cycles of adriamycin - taxol as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 2001; 69: 298 (abstr. 508).Untch M, Konecny G, Ditsch N et al. Dose - dense sequential epirubicin - paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21: abstr. 133.Eirmann W, Gianni L, Semiglazov V et al. European cooperative trial in operable breast cancer (ECTO). Proc Am Soc Clin Oncol 2003; 22: abstr. 37.Cals L, Nouyrigat P, Tchiknavorian X et al. Neoadjuvant weekly paclitaxel and epirubicin in patients with inflammatory and T4 breast cancer (IBC-T4BC): Results of a VAR Cancer Society trial. Proc Am Soc Oncol 2004; 23: abstr. 719.Frasci G, D’Aiuto G, Comella P et al. Two - month cisplatin - epirubicin - paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study. Proc Am Soc Clin Oncol 2004; 23: abstr. 601.Bear H.D, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from the National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21: 4165-74.Hutcheon A.W, Heys S.D, Sarkar T.K et al. Docetaxel primary chemotherapy in breast cancer: A five year update of the Abeerden Trial. Breast Cancer Res Treat 2003; 82: S9 (suppl. 1, abstr. 11).Von Minckwitz G, Raab G, Schuette M et al. Dose - dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0) - primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 2002; 21: abstract 168.Von Minckwitz, Raab G, Blohmer et al. In vivo chemosensivity adapted neoadjuvant chemotherapy (docetaxel - doxorubicin - cyclophosphamide followed by vinorelbine - capecitabine salvage therapy) in patients with primary breast cancer: Results of the GEPAR-TRIO randomized study. Breast Cancer Res Treat 2003; 82: S54 (suppl, abstr 236).Borrega P, Lorenzo A, Madronal C et al. Dose - dense neoadjuvant treatment with biweekly docetaxel (T) plus epirubicin (E) for locally advanced breast cancer (LABC). An ONCOPAZ Cooperative Group Study. Proc Am Soc Clin Oncol 2004; 23 (abstr. 736).Estevez L.G, Sanchez-Rovira P, Domine M et al. Neoadjuvant chemotherapy with biweekly docetaxel (D) and Gemcitabine (G) in stage II and III breast cancer: a phase II clinical trial with pharmacogenomic study. Proc Am Soc Clin Oncol 2003; 22: abstr. 248.Garcia Mata J, Calvo L, Mel J.R et al. Biweekly administration of doxorubicin plus docetaxel (AT) as neoadjuvant treatment of stage IIB and III breast cancer (BC). Proc Am Soc Clin Oncol 2003; 22: abstr. 249.Buzdar A.U, Hunt K, Smith T et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline - containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with Her/2 positive disease. Proc Am Soc Clin Oncol 2004; 23: abstr. 520.Sendman A.D, Tiersten A., Hudis C et al. Phase II trial of paxlitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81.Slamon D.J, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her-2-neu. N Engl J Med 2001; 344: 783-92.Hurley J, Doliny P, De Zarraga F et al. Platinum salts and docetaxel as primary therapy of locally advanced and inflammatory breast cancer: the final report of three sequential studies. Proc Am Soc Clin Oncol 2003; 22: abstr. 238.Lee H.G, Lee J.J, Jung K-H et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Proc Am Soc Clin Oncol 2004; 23: abstr. 607.Limentani S.A, Brufsky A.M, Erban J.K et al. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support. Proc Am Soc Clin Oncol 2003; 22: abstr. 251.